HEMLIBRA Subcutaneous injection General Drug Use Surveillance(in Hemophilia A with Inhibitors)

Trial Profile

HEMLIBRA Subcutaneous injection General Drug Use Surveillance(in Hemophilia A with Inhibitors)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 May 2018

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 22 May 2018 Status changed from planning to recruiting.
    • 27 Mar 2018 New trial record
    • 23 Mar 2018 According to a Chugai Pharmaceutical media release, results of the surveillance will be reported to the regulatory authorities, and the data shall be announced at future scientific meetings.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top